"If the efficacy is demonstrated, we will have 100 million doses for the Brazilian population," the ministry said in a statement, explaining that it had accepted a proposal from the laboratory and the British embassy in Brazil to cooperate in the technological development of the so-called ChAdOx1 vaccine, Xinhua reported.
At a press conference, the Secretary of Health Surveillance Arnaldo Correia de Medeiros explained that the Oswaldo Cruz Foundation (Fiocruz) will manufacture the vaccine using foreign technology.
If testing shows the vaccine is effective, Brazil will initially receive 30.4 million doses in two batches: 15.2 million in December 2020 and the rest in January 2021, with a value of about $127 million.
The Ministry of Health said that it will buy another 70 million doses, for a total of 100 million, at an estimated price of $2.30 per dose.
The vaccine project is currently in phase 3 of development, the last phase before approval and distribution, and testing began this week with the participation of Brazilian volunteers in a study carried out by the Federal University of Sao Paulo.
On Friday, the World Health Organization stated that this is the vaccine that is at the most advanced stage of development.
Brazil has so far reported over 55,000 deaths from the novel coronavirus and more than 1.2 million cases.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.